Each group included 1,223 patients (751 PE patients and 472 DVT patients), who were an average of 64 years old. Patients were identified from the Truven MarketScan Hospital Drug Database between November, 2012, and December, 2013. The study evaluated 2,446 people who were admitted to the hospital following a primary VTE diagnosis and were treated with either Xarelto or warfarin. Published research in Thrombosis & Haemostasis shows VTEs cost the US healthcare system between $13.5 and $27.2 billion a year. VTE affects more than 900,000 Americans each year and one-third of the episodes will be fatal, according to Janssen. "Venous thromboembolism, or VTE, represents a tremendous burden to our healthcare system, as the cost of treating these blood clots remains so high," said Steven Deitelzweig, MD, system chairman of hospital medicine and medical director of regional business development at the Ochsner Clinic Foundation in New Orleans, La. Related: Xarelto reduces hospital stays: Study The economic analysis, presented earlier this month at Hospital Medicine 2016, compared the cost savings associated with treatment with Xarelto, a non-vitamin K antagonist oral anticoagulant (NOAC), to warfarin in hospitals. US hospitals using rivaroxaban (Xarelto, Janssen Pharmaceuticals) instead of warfarin (Coumadin, Bristol-Myers Squibb) to treat patients diagnosed with a venous thromboembolism (VTE) may save nearly $2,000 per patient and shorten a patient’s hospital stay by approximately 1.5 days, according to a new study.
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |